A5048798659- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Immunotherapy and Immune Responses
- Glioma Diagnosis and Treatment
- Cancer Research and Treatments
- Virus-based gene therapy research
- Melanoma and MAPK Pathways
- Brain Metastases and Treatment
- Cancer Genomics and Diagnostics
- Computational Drug Discovery Methods
- Cancer Research and Treatment
- Immune cells in cancer
- Colorectal Cancer Treatments and Studies
- Immune Cell Function and Interaction
- PARP inhibition in cancer therapy
- Monoclonal and Polyclonal Antibodies Research
- Genetic factors in colorectal cancer
- Cutaneous Melanoma Detection and Management
- Radiomics and Machine Learning in Medical Imaging
- Single-cell and spatial transcriptomics
- Cancer, Hypoxia, and Metabolism
- Ferroptosis and cancer prognosis
- Lung Cancer Treatments and Mutations
- vaccines and immunoinformatics approaches
University Hospital of Lausanne
2016-2025
Hôpital Orthopédique de la Suisse Romande
2013-2025
Ludwig Cancer Research
2016-2025
University of Lausanne
2012-2025
Swiss Cancer Center Léman
2022-2025
École Polytechnique Fédérale de Lausanne
2015-2024
Agora
2024
SIB Swiss Institute of Bioinformatics
2015-2023
Idiap Research Institute
2023
AC Immune (Switzerland)
2018
Rechallenge with temozolomide (TMZ) at first progression of glioblastoma after chemoradiotherapy (TMZ/RT→TMZ) has been studied in retrospective and single-arm prospective studies, applying continuously or using 7/14 21/28 days schedules. The DIRECTOR trial sought to show superiority the regimen.Patients TMZ/RT→TMZ least two maintenance cycles were randomized Arm A [one week on (120 mg/m(2) per day)/one off] B [3 weeks (80 off]. primary endpoint was median time-to-treatment failure (TTF)...
T cells promote immunosuppression in melanoma through CSF1 induction and macrophage recruitment.
Tumor lymphangiogenesis, a driver of immunosuppression and metastasis, also potentiates immunotherapy.
Immune checkpoint inhibitors (ICIs) have revolutionised cancer therapy but frequently cause immune-related adverse events (irAEs). Description of late-onset and duration irAEs in the literature is often incomplete.To investigate reporting incidence long-lasting irAEs, we reviewed all registration trials leading to ICI's approval by US FDA and/or EMA up December 2019. We analysed real-world data from lung (LC) melanoma (Mel) patients treated with approved ICIs at University Hospital Lausanne...
Human cells produce thousands of lipids that change during cell differentiation and can vary across individual the same type. However, we are only starting to characterize function these cell-to-cell differences in lipid composition. Here, measured lipidomes transcriptomes human dermal fibroblasts by coupling high-resolution mass spectrometry imaging with single-cell transcriptomics. We found variations specific metabolic pathways contribute establishment states involved organization skin...
Immunotherapies have shown remarkable, albeit tumor-selective, therapeutic benefits in the clinic. Most patients respond transiently at best, highlighting importance of understanding mechanisms underlying resistance. Herein, we evaluated effects engineered immunocytokine PD1-IL2v a mouse model de novo pancreatic neuroendocrine cancer that is resistant to checkpoint and other immunotherapies. utilizes anti-PD-1 as targeting moiety fused an immuno-stimulatory IL-2 cytokine variant (IL2v)...
Adoptive cell therapy (ACT) using ex vivo–expanded tumor-infiltrating lymphocytes (TILs) can eliminate or shrink metastatic melanoma, but its long-term efficacy remains limited to a fraction of patients. Using longitudinal samples from 13 patients with melanoma treated TIL-ACT in phase 1 clinical study, we interrogated cellular states within the tumor microenvironment (TME) and their interactions. We performed bulk single-cell RNA sequencing, whole-exome spatial proteomic analyses pre-...
EORTC 26082 assessed the activity of temsirolimus in patients with newly diagnosed glioblastoma harboring an unmethylated O6 methylguanine-DNA-methyltransferase (MGMT) promoter.Patients (n = 257) fulfilling eligibility criteria underwent central MGMT testing. Patients 111) were randomized 1:1 between standard chemo-radiotherapy temozolomide or radiotherapy plus weekly (25 mg). Primary endpoint was overall survival at 12 months (OS12). A positive signal considered >38 alive per protocol...
Many human cancers manifest the capability to circumvent attack by adaptive immune system. In this work, we identified a component of evasion that involves frequent up-regulation fragile X mental retardation protein (FMRP) in solid tumors. FMRP represses attack, as revealed cancer cells engineered lack its expression. FMRP-deficient tumors were infiltrated activated T impaired tumor growth and enhanced survival mice. Mechanistically, FMRP's immunosuppression was multifactorial, involving...
BackgroundProgrammed cell death protein 1(PD-1) axis blockade has become the mainstay in treatment of recurrent and/or metastatic (R/M) head and neck squamous cancer (HNSCC). PD-L1 is only approved biomarker for patient selection; however, response rate limited even among high expressors. Our primary objective was to investigate association immune-cell-related biomarkers tumor microenvironment with PD-1 checkpoint inhibitors' outcomes patients R/M HNSCC.Patients methodsNCT03652142 a...
Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) is effective in patients melanoma, although long-term responses seem restricted who have complete remissions. Many develop secondary resistance to TIL-ACT but the involved mechanisms are unclear. In this study, we describe a case of possibly due intratumoral heterogeneity and selection resistant tumor clone by transferred T cells. To best our knowledge, first clonal pre-existing nondominant clone; report demonstrates...
Organoid tumor models have emerged as a powerful tool in the fields of biology and medicine such 3D structures grown from cells recapitulate better characteristics, making these tumoroids unique for personalized cancer research. Assessment their functional behavior, particularly protein secretion, is significant importance to provide comprehensive insights. Here, label-free spectroscopic imaging platform presented with advanced integrated optofluidic nanoplasmonic biosensor that enables...
Pancreatic neuroendocrine tumors (PanNET) comprise two molecular subtypes, relatively benign islet (IT) and invasive, metastasis-like primary (MLP) tumors. Until now, the origin of aggressive MLP has been obscure. Herein, using multi-omics approaches, we revealed that arise from IT via dedifferentiation following a reverse trajectory along developmental pathway β cells, which results in acquisition progenitor-like phenotype. Functionally, miR-181cd cluster induces IT-to-MLP transition by...